Comments
As companies across the globe step on the gas to deliver a Covid-19 vaccine, Russia has said it competed trials on its vaccine candidate, according to Russian news agency TASS.
“Clinical trials of vaccine against the novel coronavirus were completed on volunteers at Sechenov University, and the results of research proved the medication’s effectiveness”, chief researcher Elena Smolyarchuk is reported to have told TASS. This was tweeted by the Russian Embassy’s office in India.
“The research has been completed and it proved that the vaccine is safe. The volunteers will be discharged on July 15 and July 20,” Smolyarchuk, who heads the Center for Clinical Research on Medications at Sechenov University, told TASS. Further, the chief researcher added the volunteers would be under medical supervision on an out-patient basis after being discharged.
The first stage of research on the vaccine at Sechenov University started on June 18, when 18 volunteers were vaccinated. The second group of 20 volunteers were vaccinated on June 23, the agency said.
A section of clinical researchers in India told BusinessLine , it was difficult to comment on the vaccine just yet without having data from the clinical trials.
The news of the Russian vaccine comes even as 150-odd vaccine candidates are in various stages of development of a Covid-19 vaccine. Some of the promising candidates listed by the World Health Organisation include, the Oxford University vaccine candidate, co-developed with AstraZeneca, Moderna-NIAID, CanSino Biological Inc/Beijing Institute of Biotechnology and Inovio Pharmaceuticals/ International Vaccine Institute. Earlier this month, China’s Sinovac had said it entered late-stage development of its vaccine in Brazil, foreign media reported.
India, too, has multiple candidates in the reckoning from Zydus Cadila, Bharat Biotech, Panacea Biotec and Serum Institute (who is also in a production and marketing collaboration with the AstraZeneca-Oxford University candidate).
The coming days will unravel how the Russian vaccine fares, as it comes under scrutiny from the international scientific community.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.